Search results

Search:
in the keywords: in vitro release

Sort By:

Limit search:

PREPARATION AND CHARACTERIZATION OF SELF-MICROEMUSIFYING DRUG DELIVERY SYSTEM (SMEDDS) OF CISPLATIN FOR ORAL USE IN OVARIAN CANCER TREATMENT

100%

Akartas I., Karasulu H. Y.

Acta Poloniae Pharmaceutica - Drug Research

2020

vol. 77

issue 1

183-193

Cisplatin is an antineoplastic drug, used for the treatment of ovarian cancer. SMEDDS has many advantages such as enhanced bioavailability, lymphatic targeting and ease of manufacture. The main objective of this study was to prepare and characterize Cisplatin loaded SMEDDS formulation and to evaluate antitumoral activity with cell viability studies. Cisplatin SMEDDS formulation was prepared and characterized physicochemically. In vitro release studies and cell viability studies were performed and evaluated. The mean droplet size of Cisplatin SMEDDS was measured as 25,4±1,9 nm and PDI was 0,241±0,018. Refractive index of the formulation was measured as 1,471±0,001. pH values of Cisplatin SMEDDS (dilution ratio 1:10 w) were measured as 5,84±0,09 and (dilution ratio 1:10 pH 6,8 PBS) 6,51±0,14. Viscosity of formulation was measured as 284 mPa. According to in vitro release studies, %78,17 of Cisplatin were released from Cisplatin SMEDDS. The formulation performed cytotoxic effect to A2780 cells; vitality was found 20,26% at 0,02 µg/mL. It was concluded that, Cisplatin SMEDDS could be beneficial for the treatment of ovarian cancer and it could be promising alternative due to its enhanced bioavailability.

Refine search results

1 Acta Poloniae Pharmaceutica - Drug Research

1 2020

1 Akartas I.

1 Karasulu H. Y.

Search results

PREPARATION AND CHARACTERIZATION OF SELF-MICROEMUSIFYING DRUG DELIVERY SYSTEM (SMEDDS) OF CISPLATIN FOR ORAL USE IN OVARIAN CANCER TREATMENT